oral minoxidil 1.25mg versus oral dutasteride 0.5mg in male androgenetic alopecia

Randomised, prospective and comparative study on low dose oral minoxidil 1.25mg versus oral dutasteride 0.5mg in male androgenetic alopecia , and to compare the pre- and post-treatment dermoscopic features in made androgenetic alopecia (AGA) - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/082884

Enrollment

400

Registered

2025-03-20

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L648- Other androgenic alopecia

Interventions

Intervention1: Oral Minoxidil: Oral route, 1.25mg, Duartion-24 weeks Control Intervention1: Oral Dutasteride: Oral route, 0.5mg, Duration-24 weeks

Eligibility

Inclusion criteria

Inclusion criteria: Age 18 to 50 years

Exclusion criteria

Exclusion criteria: Patients with Hypertension,history of Cancer History of any oral, topical, procedural therapy in the past six months

Design outcomes

Primary

Measure	Time frame
Change in hair count per cm Change in hair diameterTimepoint: Baseline, 4 weeks,8 Weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks	—

Secondary

Measure	Time frame
Global photography assessment Timepoint: Baseline and 24 weeks	—

Countries

India

Contacts

Public ContactDr Abhijeet Kumar Jha

Patna Medical College

drabhijeetjha@gmail.com9631444797

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026